Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Hundreds of people in the UK with a rare and incurable type of blood cancer are set to benefit from a new drug that h ...
Pfizer Inc on Tuesday raised its annual guidance, as it reported strong growth in quarterly sales. The New York City ...
ridge, Surrey-based consumer healthcare firm spun-out of GSK PLC in 2022 - Announces it has completed an off-market pu ...
Pfizer Inc sold a 7.6% stake in consumer health products firm Haleon PLC for GBP2.7 billion, the investment banks run ...
Pfizer Inc on Monday said it plans to sell a 5.9% stake in consumer products firm, Haleon PLC, in a deal that could r ...
A multimillion-pound legal battle between rival developers of Covid-19 jabs over vaccine technology patents is set to ...
Pfizer Inc on Monday reported positive results from patients involved in phase 2 studies of ponsegromab and Braftovi ...
Pfizer Inc upped its yearly outlook on the back of a "strong" second-quarter, and the pharmaceutical firm added that ...
Pfizer Inc reported a drop in profit on lower sales of Covid-19 related profit Wednesday as it steers investments to ...
A row between pharmaceutical firms Moderna Inc and Pfizer Inc/BioNTech comes to court in London on Tuesday over paten ...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.35 | -1.33843212237 | 26.15 | 26.15 | 25.3 | 1831585 | 26.13593976 | DE |
| 4 | -1.05 | -3.91061452514 | 26.85 | 26.85 | 24.65 | 506834 | 26.0510158 | DE |
| 12 | -3.2 | -11.0344827586 | 29 | 30.6 | 24.65 | 524597 | 28.08989099 | DE |
| 26 | -3.55 | -12.0954003407 | 29.35 | 30.95 | 24.65 | 294202 | 28.29477827 | DE |
| 52 | -3.6 | -12.2448979592 | 29.4 | 30.95 | 24.65 | 324450 | 27.82246536 | DE |
| 156 | -28.745 | -52.69960583 | 54.545 | 60.675 | 24.65 | 291934 | 36.49506677 | DE |
| 260 | -12.7 | -32.987012987 | 38.5 | 60.675 | 24.65 | 194156 | 36.95466526 | DE |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
